Trials / Completed
CompletedNCT00733902
Tanezumab in Osteoarthritis of the Knee
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF TANEZUMAB IN PATIENTS WITH OSTEOARTHRITIS OF THE KNEE
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 697 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
Test the efficacy and safety of 3 doses in Osteoarthritis of the knee in patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | tanezumab | IV tanezumab 10 mg at 1 dose every 8 weeks |
| BIOLOGICAL | tanezumab | IV tanezumab 5 mg at 1 dose every 8 weeks |
| BIOLOGICAL | tanezumab | IV tanezumab 2.5 mg at 1 dose every 8 weeks |
| BIOLOGICAL | Placebo | IV placebo to match tanezumab at 1 dose every 8 weeks |
Timeline
- Start date
- 2008-09-15
- Primary completion
- 2009-08-24
- Completion
- 2010-01-14
- First posted
- 2008-08-13
- Last updated
- 2021-03-22
- Results posted
- 2021-03-22
Locations
82 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00733902. Inclusion in this directory is not an endorsement.